BR112021026480A2 - Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer - Google Patents
Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncerInfo
- Publication number
- BR112021026480A2 BR112021026480A2 BR112021026480A BR112021026480A BR112021026480A2 BR 112021026480 A2 BR112021026480 A2 BR 112021026480A2 BR 112021026480 A BR112021026480 A BR 112021026480A BR 112021026480 A BR112021026480 A BR 112021026480A BR 112021026480 A2 BR112021026480 A2 BR 112021026480A2
- Authority
- BR
- Brazil
- Prior art keywords
- anamycin
- reconstituting
- preparing
- effective dose
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868190P | 2019-06-28 | 2019-06-28 | |
| PCT/US2020/039621 WO2020264161A1 (en) | 2019-06-28 | 2020-06-25 | Method of reconstituting liposomal annamycin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026480A2 true BR112021026480A2 (pt) | 2022-02-08 |
Family
ID=74061076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026480A BR112021026480A2 (pt) | 2019-06-28 | 2020-06-25 | Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12257262B2 (enExample) |
| EP (1) | EP3990041B1 (enExample) |
| JP (1) | JP7830131B2 (enExample) |
| KR (1) | KR20220027941A (enExample) |
| CN (2) | CN116785242A (enExample) |
| AU (2) | AU2020302784A1 (enExample) |
| BR (1) | BR112021026480A2 (enExample) |
| CA (1) | CA3144443A1 (enExample) |
| ES (1) | ES3049663T3 (enExample) |
| IL (1) | IL289433B2 (enExample) |
| MX (1) | MX2021015667A (enExample) |
| PL (1) | PL3990041T3 (enExample) |
| SG (1) | SG11202113005SA (enExample) |
| TW (2) | TW202500161A (enExample) |
| WO (1) | WO2020264161A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020264161A1 (en) | 2019-06-28 | 2020-12-30 | Donald Picker | Method of reconstituting liposomal annamycin |
| EP3989978B1 (en) | 2019-06-28 | 2025-12-17 | Board of Regents, The University of Texas System | Preparation of preliposomal annamycin lyophilizate |
| AU2020386092A1 (en) * | 2019-11-21 | 2022-06-16 | Board Of Regents, The University Of Texas System | Lung targeted anticancer therapies with liposomal annamycin |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US4863739A (en) | 1987-05-19 | 1989-09-05 | Board Of Regents, The University Of Texas System | Liposome compositions of anthracycline derivatives |
| IS1685B (is) * | 1990-12-11 | 1998-02-24 | Bracco International B.V. | Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum |
| US5902604A (en) | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| WO2001032145A1 (en) * | 1999-10-29 | 2001-05-10 | Board Of Regents, The University Of Texas System | Method of cancer treatment |
| AU2004212944B2 (en) * | 2003-02-14 | 2008-08-21 | Children's Hospital & Research Center At Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| US20130045937A1 (en) * | 2010-03-10 | 2013-02-21 | Cempra Pharmaceuticals, Inc. | Parenteral formulations of macrolide antibiotics |
| PT4241849T (pt) * | 2011-10-14 | 2024-10-30 | Hoffmann La Roche | Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo |
| KR102284689B1 (ko) * | 2011-10-21 | 2021-08-02 | 셀라토 파마슈티칼즈, 인코포레이티드 | 동결건조된 리포좀 |
| US8926994B2 (en) | 2011-12-07 | 2015-01-06 | The Methodist Hospital Research Institute | Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| CN107569508A (zh) * | 2016-07-05 | 2018-01-12 | 江苏竞诺择生物医药科技有限公司 | 一种治疗造血系统增殖性疾病的药用组合物 |
| AU2017324718B2 (en) * | 2016-09-09 | 2022-09-29 | Irisys, Inc. | Lipsomal anticancer compositions |
| WO2019023873A1 (zh) * | 2017-07-31 | 2019-02-07 | 江苏竞诺择生物医药科技有限公司 | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物 |
| UA129837C2 (uk) | 2018-09-04 | 2025-08-20 | Мінерва Ньюросаєнсиз, Інк. | Способи застосування феноксипропіламінової сполуки для лікування болю |
| WO2020264161A1 (en) | 2019-06-28 | 2020-12-30 | Donald Picker | Method of reconstituting liposomal annamycin |
| EP3989978B1 (en) | 2019-06-28 | 2025-12-17 | Board of Regents, The University of Texas System | Preparation of preliposomal annamycin lyophilizate |
| AU2020386092A1 (en) | 2019-11-21 | 2022-06-16 | Board Of Regents, The University Of Texas System | Lung targeted anticancer therapies with liposomal annamycin |
-
2020
- 2020-06-25 WO PCT/US2020/039621 patent/WO2020264161A1/en not_active Ceased
- 2020-06-25 ES ES20832031T patent/ES3049663T3/es active Active
- 2020-06-25 PL PL20832031.7T patent/PL3990041T3/pl unknown
- 2020-06-25 JP JP2021577862A patent/JP7830131B2/ja active Active
- 2020-06-25 CN CN202310738252.3A patent/CN116785242A/zh active Pending
- 2020-06-25 CN CN202080048890.7A patent/CN114728101B/zh active Active
- 2020-06-25 IL IL289433A patent/IL289433B2/en unknown
- 2020-06-25 BR BR112021026480A patent/BR112021026480A2/pt unknown
- 2020-06-25 SG SG11202113005SA patent/SG11202113005SA/en unknown
- 2020-06-25 AU AU2020302784A patent/AU2020302784A1/en active Pending
- 2020-06-25 KR KR1020227000486A patent/KR20220027941A/ko active Pending
- 2020-06-25 EP EP20832031.7A patent/EP3990041B1/en active Active
- 2020-06-25 CA CA3144443A patent/CA3144443A1/en active Pending
- 2020-06-25 MX MX2021015667A patent/MX2021015667A/es unknown
- 2020-06-29 TW TW113132623A patent/TW202500161A/zh unknown
- 2020-06-29 TW TW109121840A patent/TWI857086B/zh active
-
2021
- 2021-12-17 US US17/554,553 patent/US12257262B2/en active Active
-
2023
- 2023-10-05 US US18/481,951 patent/US11980634B2/en active Active
-
2024
- 2024-05-29 AU AU2024203593A patent/AU2024203593B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202113005SA (en) | 2021-12-30 |
| ES3049663T3 (en) | 2025-12-17 |
| CN116785242A (zh) | 2023-09-22 |
| IL289433A (en) | 2022-02-01 |
| TW202114704A (zh) | 2021-04-16 |
| IL289433B2 (en) | 2026-05-01 |
| AU2020302784A1 (en) | 2022-01-20 |
| US20220105116A1 (en) | 2022-04-07 |
| MX2021015667A (es) | 2022-04-18 |
| US11980634B2 (en) | 2024-05-14 |
| IL289433B1 (en) | 2026-01-01 |
| CN114728101A (zh) | 2022-07-08 |
| WO2020264161A1 (en) | 2020-12-30 |
| TW202500161A (zh) | 2025-01-01 |
| US12257262B2 (en) | 2025-03-25 |
| PL3990041T3 (pl) | 2026-02-23 |
| CN114728101B (zh) | 2023-07-14 |
| JP2023523872A (ja) | 2023-06-08 |
| EP3990041A1 (en) | 2022-05-04 |
| AU2024203593B2 (en) | 2025-08-14 |
| EP3990041A4 (en) | 2023-07-12 |
| CA3144443A1 (en) | 2020-12-30 |
| EP3990041B1 (en) | 2025-08-06 |
| JP7830131B2 (ja) | 2026-03-16 |
| TWI857086B (zh) | 2024-10-01 |
| AU2024203593A1 (en) | 2024-07-11 |
| US20240024345A1 (en) | 2024-01-25 |
| KR20220027941A (ko) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123586T1 (el) | Υποδορια σκευασματα αντισωματος her2 | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| CA3055791A1 (en) | Treatment methods | |
| BR112021017375A2 (pt) | Composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer | |
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| CY1122038T1 (el) | Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4 | |
| BR112017028530A2 (pt) | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| EP4286008A3 (en) | Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| MX2024014238A (es) | Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer | |
| BR112018068412A2 (pt) | composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| WO2019200314A3 (en) | Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| ZA202108677B (en) | Method of treating tumours | |
| PH12018500254A1 (en) | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof | |
| BR112022013646A2 (pt) | Método de tratamento de esplenomegalia | |
| WO2017098051A3 (en) | Combined preparations of pkm2 modulators and hmgb1 | |
| EP4295903A3 (en) | Compositions and methods for treating farber disease | |
| PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
| MX2023006087A (es) | Formulaciones liofilizadas de tegavivint. | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| MX2021004396A (es) | Metodos y composiciones para el tratamiento de la mucositis oral. | |
| EA202092540A1 (ru) | Комбинации для лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |